• Castle Biosciences President and CEO Derek J. Maetzold sold 14,496 common shares on Nov. 2, 2026.
• Sales comprised 12,764 shares at $36.005 per share and 1,732 shares at $36.814 per share.
• Following the transactions, Maetzold held 3,904 shares directly and 152,038 shares indirectly through trusts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-070131), on November 04, 2026, and is solely responsible for the information contained therein.